Olymvax Biopharmaceuticals released its semi-annual performance, with a net profit attributable to the parent company of 13.2 million yuan, turning a profit from a loss year-on-year
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Olymvax Biopharmaceuticals disclosed its semi-annual report for 2025, reporting revenue of 306 million yuan, a year-on-year increase of 35.17%; net profit attributable to the parent company of 13.2 million yuan, turning from loss to profit year-on-year; net profit excluding non-recurring items of 7.72 million yuan, also turning from loss to profit year-on-year; basic earnings per share of 0.0326 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments